%0 Journal Article
%T 三阴性乳腺癌的耐药机制及与DLG5的研究进展<br>Drug Resistance Mechanism of Tri-ple-Negative Breast Cancer and Research Progress with DLG5
%A 王旭升
%A 陈波
%A 车景敏
%A 王虎霞
%A 徐翠香
%A 宋张骏
%J Advances in Clinical Medicine
%P 18067-18076
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.13112537
%X 三阴性乳腺癌(Triple Negative Breast Cancer, TNBC)是乳腺癌的一种特定亚型，因其不表达雌激素受体 (Estrogen Receptor, ER)、孕酮受体(Progesterone Receptor, PR)或人表皮生长因子受体-2 (Epi-dermal Growth Factor Receptor, HER-2)具有高侵袭能力，预后较其他类型乳腺癌差，在治疗上往往因为出现耐药性导致癌症进展和复发。早期应用化疗药物对三阴性乳腺癌有明显治疗效果，但随着化疗药物的应用，患者可逐渐出现耐药，导致总体生存率低下。因此，研究三阴性乳腺癌的化疗耐药性是目前乳腺癌的关注热点。本文回顾了三阴性乳腺癌耐药的研究进展，特别是极性蛋白DLG5在三阴性乳腺癌耐药中的作用以及影响，以期为临床治疗提供参考。<br />
Triple negative breast cancer (TNBC) is a specific subtype of breast cancer because it does not ex-press estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor re-ceptor (epidermal growth factor receptor, HER-2) has high aggressiveness, has a worse prognosis than other types of breast cancer, and is often treated because of drug resistance leading to cancer progression and recurrence. Early use of chemotherapy drugs has a significant therapeutic effect on triple-negative breast cancer, but with the application of chemotherapy drugs, patients can gradu-ally develop drug resistance, resulting in low overall survival. Therefore, the study of chemotherapy resistance in triple-negative breast cancer is currently a hot spot in breast cancer. This article re-views the research progress of triple-negative breast cancer drug resistance, especially the role and impact of polar protein DLG5 in triple-negative breast cancer drug resistance, in order to provide reference for clinical treatment.
%K 三阴性乳腺癌，DLG5，耐药机制<br>Triple-Negative Breast Cancer
%K DLG5
%K Mechanisms of Drug Resistance
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=75700